Original Research

Online Information About Hydroquinone: An Assessment of Accuracy and Readability

Author and Disclosure Information

Practice Points

  • Hydroquinone (HQ) 4% is US Food and Drug Administration (FDA) approved for skin hyperpigmentation including melasma.
  • In September 2020, the FDA enforced the CARES (Coronavirus Aid, Relief, and Economic Security) Act and OTC (over-the-counter) Monograph Reform, announcing that HQ is not classified as Category II/not generally recognized as safe and effective, thus prohibiting the distribution of OTC HQ products.
  • Exogenous ochronosis is a potential side effect associated with HQ.
  • There is a need for dermatologists to develop online patient education materials on HQ that are characterized by high-quality and up-to-date medical information.


 

References

To the Editor:

The internet is a popular resource for patients seeking information about dermatologic treatments. Hydroquinone (HQ) cream 4% is approved by the US Food and Drug Administration for skin hyperpigmentation.1 The agency enforced the CARES (Coronavirus Aid, Relief, and Economic Security) Act and OTC (over-the-counter) Monograph Reform on September 25, 2020, to restrict distribution of OTC HQ.2 Exogenous ochronosis is listed as a potential adverse effect in the prescribing information for HQ.1

Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram of the article selection process

Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram of the article selection process

We sought to assess online resources on HQ for accuracy of information, including the recent OTC ban, as well as readability. The word hydroquinone was searched on 3 internet search engines—Google, Yahoo, and Bing—on December 12, 2020, each for the first 20 URLs (ie, websites)(total of 60 URLs). Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)(Figure) reporting guidelines were used to assess a list of relevant websites to include in the final analysis. Website data were reviewed by both authors. Eighteen duplicates and 27 irrelevant and non–English-language URLs were excluded. The remaining 15 websites were analyzed. Based on a previously published and validated tool, a pro forma was designed to evaluate information on HQ for each website based on accountability, quality, readability, display, support, and transparency (Table).1,3

Pro Forma to Evaluate Websites for Information on Hydroquinone1

Scores for all 15 websites are listed in eTable 1. The mean overall (total) score was 25.3 points (of a maximum possible score of 44 points; range, 18–34). The average accountability score was 6.3 (of a possible 10; range, 3–10); average quality score, 10.9 (of a possible 17; range, 5–16); and average readability score, 2.1 (of a possible 5; range, 0–5).

Scores for 15 Websites With Information on Hydroquinone
Scores for 15 Websites With Information on Hydroquinone

The mean display score was 0.3 (of a possible 4; range, 0–2); 66.7% of websites (10/15) had advertisements or irrelevant material. Only 6.7% and 13.3% of websites included relevant videos or images, respectively, on applying HQ (eTable 2). We identified only 3 photographs—across all 15 websites—that depicted skin, all of which were Fitzpatrick skin types II or III. Therefore, none of the websites included a diversity of images to indicate broad ethnic relatability.

Pro Forma Criteria for 15 Websites With Information on Hydroquinone

The average support score was 2.5 (of a possible 4; range, 1–3); 20% (3/15) of URLs included chat sites, message boards, or forums, and approximately half (8/15 [53.3%]) included references. Only 7 URLs (46.7%) had been updated in the last 12 months. Only 4 (26.7%) were written by a board-certified dermatologist (eTable 2). Most (60%) websites contained advertising, though none were sponsored by a pharmaceutical company that manufactures HQ.

Only 46.7% (7/15) of websites recommended limiting a course of HQ treatment to 3 months; only 40% (6/15) mentioned shelf life or photochemical degradation when exposed to air. Although 93.3% (14/15) of URLs mentioned ochronosis, a clinical description of the condition was provided in only 33.3% (5/15)—none with images.

Only 2 sites (13.3%; Everyday Health and WebMD) met the accepted 7th-grade reading level for online patient education material; those sites scored lower on quality (9 of 17 and 6 of 17, respectively) than sites with higher overall scores.

Pages

Recommended Reading

Expect Ellacor’s applications to be wide-ranging, expert predicts
MDedge Dermatology
Forceps for Milia Extraction
MDedge Dermatology
‘Cool’ way of eradicating fat a promising therapy for many medical conditions
MDedge Dermatology
Fractional lasers appear to treat more than a fraction of skin, expert says
MDedge Dermatology
Can lasers be used to measure nerve sensitivity in the skin?
MDedge Dermatology
What’s ahead for laser-assisted drug delivery?
MDedge Dermatology
Pending further study, caution recommended in treating vitiligo patients with lasers, IPL
MDedge Dermatology
Adhesive Tape to Guide Injection Depth of Botulinum Toxin for Axillary Hyperhidrosis
MDedge Dermatology
Is benzophenone safe in skin care? Part 2: Environmental effects
MDedge Dermatology
FDA cautions against using OTC products to remove skin spots, moles
MDedge Dermatology